Safety of fluoroquinolones in paediatrics

Expert Opinion on Drug Safety

Volumn 1, Issue 4, 2002, Pages 319-324

  Cuzzolin, Laura ^a   Fanos, Vassilios ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

arthropathy; children; ciprofloxacin; fluoroquinolones; norfloxacin; ofloxacin; paediatrics; pefloxacin; side effects

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADOLESCENT; CHEMICALLY INDUCED DISORDER; CHILD; DRUG HYPERSENSITIVITY; DRUG INTERACTION; EXPERT WITNESS; FEMALE; HUMAN; MALE; NEUROPATHIC JOINT DISEASE; PATHOPHYSIOLOGY; PEDIATRICS; PRESCHOOL CHILD; REVIEW; SAFETY; STRUCTURE ACTIVITY RELATION;

ADOLESCENT; ANTI-INFECTIVE AGENTS; ARTHROPATHY, NEUROGENIC; CHILD; CHILD, PRESCHOOL; DRUG HYPERSENSITIVITY; DRUG INTERACTIONS; EXPERT TESTIMONY; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; PEDIATRICS; SAFETY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0042235479     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.1.4.319     Document Type: Review

References (65)

1. SCHAAD UB, SALAM MA, AUJARD Y: Use of fluoroquinolones in pediatrics: consensus report of the International Society of Chemotherapy Commission. Pediatr. Infect. Dis. J. (1995) 14:1-9.
2. BURKHARDT JE, WALTERSPIEL JN, SCHAAD UB: Quinolone arthropathy in animals versus children. Clin. Infect Dis. (1997) 25:1196-1204. (Pubitemid 27513209)
3. NELSON JD, MCCRACKEN GH: Fluoroquinolones in pediatrics. Pediatr. Infect. Dis. J. (1998). Newsletter.
4. SCHAAD UB: Use of the quinolones in pediatrics. In: The Quinolones (2nd edn). Andriole VT (Ed.), Academic Press, San Diego (1998):351-367.
5. BALL P, TILLOTSON G: Tolerability of fluoroquinolone antibiotics. Drug Saf. (1995) 13:343-358.
6. BALL P, MANDELL L, NIKI Y, TILLOTSON G: Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf (1999) 21:407-421. (Pubitemid 29520901)
7. BREEN J, SKUBA K, GRASELA D: Safety and tolerability of gatifloxacin, an advanced third-generation 8-methoxy fluoroquinolone. J. Resp. Dis. (1999) 20(Suppl. 11):S70-S76.
8. BLUM MD, GRAHAM DJ, MCCLOSKEY CA: Temafloxacin syndrome: review of 95 cases. Clin. Infect. Dis. (1994) 18:946-950. (Pubitemid 24171342)
9. STAHLMANN R, SCHWABE R: Safety profile of grepafloxacin compared with other fluoroquinolones. J. Antimicr. Chemother. (1997) 40(Suppl. A):83-92. (Pubitemid 28041171)
10. LIPSKY BA, DORR MB, MAGNER DJ, TALBOT GH: Safety profile of sparfloxacin, a new fluoroquinolone antibiotic. Clin. Ther. (1999) 21:148-159. (Pubitemid 29106697)
11. BALL P: Quinolone generations: natural history or natural selection? J. Antimicr. Chemother. (2000) 46:17-24. (Pubitemid 30468444)
12. DOMAGALA JM: Structure-activity and structure-side effect relationships for the quinolone antibacterials. J. Antimicr. Chemother. (1994) 33:685-706. (Pubitemid 24149805)
13. ZHANEL GG, ENNIS K, VERCAIGNE L et al: A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs (2002) 62(1): 13-59. (Pubitemid 34169425)
14. WILTON LV, PEARCE GL, MANN RD: A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br. J. Clin. Pharmacol. (1996) 41:277-284. (Pubitemid 26114816)
15. LOFFELD RJLF, FLENDRIG JA: [Pseudomembranous colitis under administration of norfloxacin]. Ned. Tijdschr Geneeskd (1990) 134:83. Dutch.
16. GOLLEDGE CL, CARSON CF, O'NEILL GL et al: Ciprofloxacin and Clostridium difficile-associated diarrhoea. J. Antimicr. Chemother. (1992) 30:141-147.
17. SCHMUCK G, SCHÜRMANN A, SCHLÜTER G: Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicr. Agents Chemother. (1998) 42:1831-1836. (Pubitemid 28311587)
18. JANKNEGT R: Drug interactions with quinolones. J. Antimicr. Chemother. (1989) 11:33-43.
19. AKAHANE K, KIMURA Y, TSUTOMI Y, HAYAKAWA I: Possible intermolecular interaction between quinolones and biphenylacetic acid inhibits gamma-aminobutyric acid receptor sites. Antimicr. Agents Chemother. (1994) 38:2323-2329. (Pubitemid 24304224)
20. MANDELL LA, BALL P, TILLOTSON G: Antimicrobial safety and tolerability: differences and dilemmas. Clin. Infect. Dis. (2001) 32(Suppl. 1):S72-S79. (Pubitemid 32506749)
21. COLEMAN CI, SPENCER JV, CHUNG JO, REDDY P: Possible gatifloxacin-induced fulminant hepatic failure. Ann. Pharmacother. (2002) 36(7):1162-1167. (Pubitemid 34755791)
22. DRICI MD, KNOLLMANN BC, WA N G W X et al.: Cardiac actions of erythromycin: influence of female sex. JAMA (1998) 280:1774-1776. (Pubitemid 28536879)
23. MATSUMOTO M, KAJIMA K, NAGANO H, MATSUBARA S, YOKOTA T: Photostability and biological activity of fluoroquinolones substituted at the 8-position after UV irradiation. Antimicr. Agents Chemother. (1992) 36:1715-1719.
24. KLECACK G, URBACH F, URWYLER H: Fluoroquinolone antibacterials enhance UVA-induced skin tumors. J. Photochem. Photobiol. (1997) 37:174-181. (Pubitemid 27117015)
25. HAYEM G, CARBON C: A reappraisal of quinolone tolerability: the experience of their musculoskeletal adverse effects. Drug Saf. (1995) 13:338-342.
26. KAHN MF, HAYEM G: Tendons and fluoroquinolones-unresolved issues. Rev. Rhum. Engl. Ed. (1997) 64:437-439.
27. MARTI H P, STOLLER R, FREY FJ: Fluoroquinolones as a cause of tendon disorders in patients with renal failure/renal transplants. Br. J. Rheumatol. (1998) 37:343-344. (Pubitemid 28371804)
28. PIERFITTE C, ROYER RJ: Tendon disorders with fluoroquinolones. Therapie (1996) 51:419-420. (Pubitemid 26300913)
29. PATON JH, REEVES DS: Adverse reactions to the fluoroquinolones. Adverse Drug React. Bull. (1992) 153:575-578.
30. FANOS V, CUZZOLIN L: Fluoroquinolones in pediatrics and their nephrotoxicity in the adult. J. Chemother. (2000) 12(2):228-231. (Pubitemid 30409186)
31. BERTINO J, FISH D: The safety profile of the fluoroquinolones. Clin. Ther. (2000) 22(7):798-817. (Pubitemid 30625913)
32. DAVIS R, MARKHAM A, BALFOUR JA: Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs (1996) 51:1019-1074.
33. BERINGER PM, WONG-BERINGER A, RHO JP: Economic aspects of antibacterial adverse effects. Pharmacoeconomics (1998) 13:35-49.
34. AVENT CK, KRINSKY D, KIRKLIN JK et al: Synergistic nephrotoxicity due to ciprofloxacin and cyclosporin A. Am. J. Med. (1988) 85:452-453.
35. JOLSON HM, TANNER LA, GREEN L, GRASELA TH: Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch. Intern. Med. (1991) 151:1003-1004.
36. NORRBY SR, LIETMAN PS: Safety and tolerability of fluoroquinolones. Drugs (1993) 45(Suppl. 3):59-64. (Pubitemid 23242917)
37. VAN ROSENSTIEL N, ADAM D: Quinolone antibacterials-an update of their pharmacology and therapeutic use. Drugs (1993) 47:371-401.
38. CHYSKY V, KAPILA K, HULLMANN R, ARCIERI G, SCHACHT P, ECHOLS R: Safety of ciprofloxacin in children: worldwide clinical experience based on a compassionate use. Emphasis on joint evaluation. Infection (1991) 19:289-296.
39. KUBIN R: Safety and efficacy of ciprofloxacin in pediatric patients: review. Infection (1993) 21:413-421.
40. MASTUNO K, YAMATOYA O, MIYATA K, HASEGAWA H, FUJITA H, YAMAUCHI K: Surveillance of adverse reactions due to ciprofloxacin in Japan. Drugs (1995) 49(Suppl. 2):495-496.
41. LIETMAN PS: Fluoroquinolone toxicities. An update. Drugs (1995) 49(Suppl. 2): 159-163.
42. JAFRI HS, MCCRACKEN GH: Fluoroquinolones in paediatrics. Drugs (1999) 58(Suppl. 2):43-48. (Pubitemid 29500084)
43. SCHAAD UB, WEDGWOOD-KRUCKO J: Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection (1987) 15:165-168. (Pubitemid 17084968)
44. CHEVALIER X, ALBENGRES E, VOISIN MC, TILLEMENT J P, LARGET-PIET B: A case of destructive polyarthropathy in a 17-year-old youth following pefloxacin treatment. Drug Saf. (1992) 7:310-314.
45. BISWAL N, MATHAI B, BHATIA BD: P-floxacin induced arthropathy. Indian Pediatr. (1993) 30:718-719. Letter.
46. CHANG H, CHUNG MH, KIM JIH, KIM JH: Pefloxacin-induced arthropathy in an adolescent with brain abscess. Scand. J. Infect. Dis. (1996) 28:641-643. (Pubitemid 27092410)
47. KARANDE S, KSHIRSARGAR NA: Ciprofloxacin use: acute arthropathy and long-term follow up. Indian Pediatr. (1996) 33:910-916.
48. ARICO M, BOSSI G, GASELLI D et al.: Long-term magnetic resonance survey of cartilage damage in leukemic children treated with fluoroquinolones. Pediatr. Infect. Dis. J. (1995) 14:713-714.
49. BHATTACHARYA K, BHATTACHARYA MK, DUTTA D et al.: Double-blind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children. Acta Paediatr. (1997) 86:319-320. (Pubitemid 27135282)
50. GREEN S, TILLOTSON G: Use of ciprofloxacin in developing countries. Pediatr. Infect. Dis. J. (1997) 16:150-159.
51. LEIBOVITZ E, JANCO J, PIGLANSKY L et al.: Oral ciprofloxacin (CIP) versus im ceftriaxone (CRO) for empirical treatment of childhood invasive diarrhea: a randomized double-blind study. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (24-27 September 1998). American Society of Microbiology. Abstract L-54.
52. HOPKINS S, WILLIAMS D, DUNNE M et al.: A randomized controlled trial of oral or iv trovafloxacin versus ceftriaxone in the treatment of epidemic meningococcal meningitis. Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, USA (24-27 September 1998). American Society of Microbiology. Abstract LB-21.
53. MULLEN CA, PETROPOULOS D, ROBERTS WM et al.: Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients. Cancer (1999) 86:126-134. (Pubitemid 29293385)
54. HEGGERS J, VILLARREAL C, EDGAR P et al.: Ciprofloxacin as a therapeutic modality in pediatric burn wound infection: efficacious or contraindicated? Arch. Surg. (1998) 133:1247-1250. (Pubitemid 28516278)
55. JICK S: Ciprofloxacin safety in the pediatric population. Pediatr. Infect. Dis. J. (1997) 16:130-134.
56. PERTUISET E, LENOIR G, JEHANNE M, DOUCHAIN F, GUILLOT M, MENKES CJ: [Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cyctic fibrosis]. Rev. Rheum. Mal. Osteoart. (1989) 56:735-740. French.
57. KESSELER A, LACASSIE A, HUGOT J P, TALON P, THOMAS D, ASTIER L: [Arthropathies following the administration of pefloxacin to an adolescent with mucoviscidosis]. Ann. Pediatr. (Paris) (1989) 36:275-278. French.
58. HOIBY N, PEDERSEN SS, JENSEN T, VALERIUS NH, KOCH C: Fluoroquinolones in the treatment of cystic fibrosis. Drugs (1993) 45(Suppl. 3):98-101. (Pubitemid 23242922)
59. RUBIO TT, MILES MV, LETTIERI JT, KUHN RJ, ECHOLS RM, CHURCH DA: Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation. Pediatr. Infect. Dis. J. (1997) 16:112-117. (Pubitemid 27063129)
60. CHURCH DA, KANGA JF, KUHN RJ, RUBIO TT, SPOHN WA, STEVENS JC: Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study versus ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr. Infect. Dis. J. (1997) 16:97-105. (Pubitemid 27063127)
61. SCHAAD UB, WEDGWOOD J, RUEDEBERG A, KRAEMER R, HAMPEL B: Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr. Infect. Dis. J. (1997) 16:106-111. (Pubitemid 27063128)
62. REDMOND AO: Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr. Infect. Dis. J. (1997) 16:147-149. (Pubitemid 27063135)
63. DAGAN R: Fluoroquinolones in pediatrics. Drugs (1995) 49(Suppl. 2):92-99.
64. PHILLIPS BM, DAVID TJ: Pathogenesis and management of arthropathy in cystic fibrosis. J. Royal Soc. Med. (1986) 79:44-50.
65. MORMILE R, CUZZOLIN L, FANOS V: Fluoroquinolones in complicated pediatric urinary tract infections: a review of the literature. Infect. Urol. (2002) 15(3):3-8.